Efficacy and safety of Id-protein-loaded dendritic cell vaccine
in patients with multiple myeloma - Phase II study results

J 2012

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results

ZAHRADOVÁ, Lenka, K. MOLLOVA, Darina OČADLÍKOVÁ, L. KOVAROVA, Zdeněk ADAM et. al.

Základní údaje

Originální název

Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results

Autoři

ZAHRADOVÁ, Lenka (203 Česká republika, garant, domácí), K. MOLLOVA (203 Česká republika), Darina OČADLÍKOVÁ (203 Česká republika, domácí), L. KOVAROVA (203 Česká republika), Zdeněk ADAM (203 Česká republika, domácí), Marta KREJČÍ (203 Česká republika, domácí), Luděk POUR (203 Česká republika, domácí), Andrea KŘIVANOVÁ (203 Česká republika, domácí), Viera SANDECKÁ (703 Slovensko, domácí) a Roman HÁJEK (203 Česká republika, domácí)

Vydání

Neoplasma, Bratislava, 2012, 0028-2685

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30200 3.2 Clinical medicine

Stát vydavatele

Slovensko

Utajení

není předmětem státního či obchodního tajemství

Impakt faktor

Impact factor: 1.574

Kód RIV

RIV/00216224:14110/12:00060980

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.4149/neo_2012_057

UT WoS

000305499900012

Klíčová slova anglicky

dendritic cells; immunotherapy; anticancer vaccines; Id-protein; multiple myeloma

Příznaky

Mezinárodní význam

Změněno: 22. 4. 2013 16:14, Soňa Böhmová

Anotace

V originále

In a phase II clinical study, pretreated multiple myeloma patients with relapsing or stable disease received autologous anticancer vaccine containing dendritic cells loaded with Id-protein. Patients received a total of 6 vaccine doses intradermally in monthly intervals. No clinical responses were observed. During the follow-up with a median of 33.1 months (range: 11-43 months), the disease remained stable in 7/11 (64%) of patients. Immune responses measured by ELISpot were noted in 3/11 (27%) and DTH skin test for Id-protein was positive in 8/11 (73%) of patients; out of those, 1/11 (9%) and 5/11 (46%), respectively, had preexisting immune response to Id-protein before the vaccination began. Outcomes were compared to those of a control group of 13 patients. A trend to lower cumulative incidence of progression in the vaccinated group was observed at 12 months from the first vaccination (p = 0.099). More patients from the control group compared to vaccinated patients required active anticancer therapy [4/11 (36%) vs. 8/13 (62%)]. Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients. Our results suggest that the vaccination could stabilize the disease in approximately two-thirds of patients.

Návaznosti

LC06027, projekt VaV

Název: Univerzitní výzkumné centrum - Česká myelomová skupina (Akronym: LC MGUS)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Univerzitní výzkumné centrum - Česká myelomová skupina (URC - CMG)

2B06058, projekt VaV

Název: Bezpečná biotechnologie alotransplantovaných hematopoetických kmenových buněk u vybraných solidních a hematologických nádorů jako adoptivní imunoterapie (Akronym: NPVII11001)

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Bezpečná biotechnologie alotransplatovaných hematopoetických kmenových buněk u vybraných solidních a hematologických nádorů jako adoptivní imunoterapie

Citovat

ZAHRADOVÁ, Lenka, K. MOLLOVA, Darina OČADLÍKOVÁ, L. KOVAROVA, Zdeněk ADAM, Marta KREJČÍ, Luděk POUR, Andrea KŘIVANOVÁ, Viera SANDECKÁ a Roman HÁJEK. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results. Neoplasma. Bratislava, 2012, roč. 59, č. 4, s. 440-449. ISSN 0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo_2012_057.

@article{992903,
   author = {Zahradová, Lenka and Mollova, K. and Očadlíková, Darina and Kovarova, L. and Adam, Zdeněk and Krejčí, Marta and Pour, Luděk and Křivanová, Andrea and Sandecká, Viera and Hájek, Roman},
   article_location = {Bratislava},
   article_number = {4},
   doi = {http://dx.doi.org/10.4149/neo_2012_057},
   keywords = {dendritic cells; immunotherapy; anticancer vaccines; Id-protein; multiple myeloma},
   language = {eng},
   issn = {0028-2685},
   journal = {Neoplasma},
   title = {Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results},
   volume = {59},
   year = {2012}
}

TY  - JOUR
ID  - 992903
AU  - Zahradová, Lenka - Mollova, K. - Očadlíková, Darina - Kovarova, L. - Adam, Zdeněk - Krejčí, Marta - Pour, Luděk - Křivanová, Andrea - Sandecká, Viera - Hájek, Roman
PY  - 2012
TI  - Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results
JF  - Neoplasma
VL  - 59
IS  - 4
SP  - 440-449
EP  - 440-449
SN  - 00282685
KW  - dendritic cells
KW  - immunotherapy
KW  - anticancer vaccines
KW  - Id-protein
KW  - multiple myeloma
N2  - In a phase II clinical study, pretreated multiple myeloma patients with relapsing or stable disease received autologous anticancer vaccine containing dendritic cells loaded with Id-protein. Patients received a total of 6 vaccine doses intradermally in monthly intervals. No clinical responses were observed. During the follow-up with a median of 33.1 months (range: 11-43 months), the disease remained stable in 7/11 (64%) of patients. Immune responses measured by ELISpot were noted in 3/11 (27%) and DTH skin test for Id-protein was positive in 8/11 (73%) of patients; out of those, 1/11 (9%) and 5/11 (46%), respectively, had preexisting immune response to Id-protein before the vaccination began. Outcomes were compared to those of a control group of 13 patients. A trend to lower cumulative incidence of progression in the vaccinated group was observed at 12 months from the first vaccination (p = 0.099). More patients from the control group compared to vaccinated patients required active anticancer therapy [4/11 (36%) vs. 8/13 (62%)]. Vaccines based on dendritic cells loaded with Id-protein are safe and induce specific immune response in multiple myeloma patients. Our results suggest that the vaccination could stabilize the disease in approximately two-thirds of patients.
ER  -

ZAHRADOVÁ, Lenka, K. MOLLOVA, Darina OČADLÍKOVÁ, L. KOVAROVA, Zdeněk ADAM, Marta KREJČÍ, Luděk POUR, Andrea KŘIVANOVÁ, Viera SANDECKÁ a Roman HÁJEK. Efficacy and safety of Id-protein-loaded dendritic cell vaccine in patients with multiple myeloma - Phase II study results. \textit{Neoplasma}. Bratislava, 2012, roč.~59, č.~4, s.~440-449. ISSN~0028-2685. Dostupné z: https://dx.doi.org/10.4149/neo\_{}2012\_{}057.

Podrobný výpis o publikaci